Redeye provides an update following Neem's Hill's Q2 2026 report. Topline came in a bit softer than expected, while the company continued to show solid cost control. We are, however, encouraged by the positive progress in the Animal Care segment. On the back of the report, we have slightly lowered our fundamental value (base case) while presenting our new Fair Value of SEK5.7, with the stock screening as "Attractively Priced".
LÄS MER
